AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player…
AstraZeneca stock drops after heart drug trial miss raises broader concerns
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug…